ACADEMIA
JSHR to Conduct 20-Year Follow-Up Study in Up to 100,000 Patients to Determine Efficacy of H. Pylori Eradication Therapy at Preventing Stomach Cancer
The Japanese Society for Helicobacter Research (JSHR) will initiate a prospective observational study to investigate the incidence of stomach cancer over time in patients who have successfully completed H. pylori eradication therapy. The JSHR will register up to 100,000 patients…
To read the full story
ACADEMIA
- Dementia Drugs See Modest Uptake in Japan amid Eligibility Limits, Safety Concerns
April 9, 2026
- Cancer Drug Supply Risks Spur Calls for Pricing Reform: JSMO
March 31, 2026
- Japan Ophthalmology Society Flags Off-Label Concerns Ahead of Upneeq Launch
March 30, 2026
- Real-World Study Backs Lecanemab Safety, 90% Stay on Treatment
March 25, 2026
- CAR-T Reimbursement Insufficient, Kyoto University Hospital Chief Warns
March 11, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





